secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001517022-24-000065
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q2 2024 net loss narrows to $8.6M; Vafseo launch on track for Jan 2025
-----------------------------------------------------------------------------

- Total revenues $43.6M (down 23% YoY); Auryxia net product rev $41.2M vs $42.2M in Q2 2023.
- Net loss $8.6M vs $11.2M in Q2 2023; cash and equivalents $39.5M as of June 30, 2024.
- Vafseo TDAPA application submitted; HCPCS codes expected Oct 2024, TDAPA by Jan 2025.
- Set Vafseo WAC at $1,278 for 30-day supply (~$15,500/year); regained full U.S. rights from CSL Vifor.
- Auryxia FY 2024 net product revenues expected in line with 2023 level ($167M in 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/0001517022-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000065/akba-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer